Sol-Gel Technologies Ltd.

Iterum Therapeutics (NASDAQ: ITRM - Get Free Report) and Sol-Gel Technologies (NASDAQ: SLGL - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation and dividends. Profitability This table compares Iterum Therapeutics and

Sol-Gel Technologies (NASDAQ: SLGL - Get Free Report)'s stock had its "buy" rating reiterated by equities research analysts at HC Wainwright in a research report issued to clients and investors on Monday, Benzinga reports. They presently have a $110.00 price target on the stock. HC Wainwright's target price would suggest a potential upside of 70.62% from

Trulieve Cannabis (NYSE: TRLV - Get Free Report) and Sol-Gel Technologies (NASDAQ: SLGL - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk. Institutional and Insider Ownership 26.2% of Sol-Gel

UGP, SCSC, MRKR, SLGL and MEOH have been added to the Zacks Rank #1 (Strong Buy) List on October 16, 2026.

Sol-Gel Technologies NASDAQ: SLGL outlined its development and commercialization plans for SGT-610, a topical patidegib treatment being studied to reduce new basal cell carcinomas (BCCs) in patients with Gorlin syndrome, a rare inherited disorder associated with recurrent skin cancers and other manifestations.

Sol-Gel Technologies Ltd. (SLGL) Analyst/Investor Day Transcript

SolGel Technologies (SLGL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Shares of Sol-Gel Technologies Ltd. (NASDAQ: SLGL - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the six research firms that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, three have assigned a buy rating

NESS ZIONA, Israel, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with rare and severe skin conditions, today announced it will host a KOL Investor Event on SGT-610 (patidegib gel, 2%) on Wednesday, October 14, 2026 in New York.

Sol-Gel Technologies (NASDAQ: SLGL - Get Free Report) and Heron Therapeutics (NASDAQ: HRTX - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, earnings and analyst recommendations. Analyst Ratings This is a summary of

SolGel Technologies (SLGL) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Last patient has completed the last scheduled study visit in the pivotal Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome Top-line results remain on track for late November 2026 NESS ZIONA, Israel, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd.

NESS ZIONA, Israel, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with rare and severe skin conditions, today announced financial results for the second quarter ended June 30, 2026, and provided a corporate update.